Esperion Therapeutics (ESPR) Tops Q3 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
November 2, 2020 4:01 PM EST Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) tablets
 U.S. Product Revenue Increased Five-fold During the Third Quarter
 ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO (bempedoic acid) and NUSTENDI (bempedoic acid and ezetimibe) in Germany, the Largest European Market
Conference Call and Webcast today, November 2nd at 4:30 P.M. Eastern Time
ANN ARBOR, Mich., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ESPERION (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2020, and... More
